# Cerus Corp: overview

CERS · Nasdaq · CIK 1020214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cers.md) · [Financials](/companies/cers/financials.md) · [Filings](/companies/cers/filings.md) · [Insiders](/companies/cers/insiders.md)

Latest reported revenue: [$57.4m](/filings/0001193125-26-326295.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-326295).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [43.2](/filings/0001193125-26-197777.md) | [52.4](/filings/0001193125-26-326295.md) | not reported | not reported | [53.7](/filings/0001193125-26-197777.md) | [57.4](/filings/0001193125-26-326295.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(13.5%)](/filings/0001193125-26-197777.md) | [(6.5%)](/filings/0001193125-26-326295.md) | not reported | not reported | [(0.7%)](/filings/0001193125-26-197777.md) | [(3.2%)](/filings/0001193125-26-326295.md) |
| Net margin | % | not reported | not reported | [(17.8%)](/filings/0001193125-26-197777.md) | [(10.9%)](/filings/0001193125-26-326295.md) | not reported | not reported | [(3.1%)](/filings/0001193125-26-197777.md) | [(5.1%)](/filings/0001193125-26-326295.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001193125-25-270039.md) | not reported | [(0.04)](/filings/0001193125-26-197777.md) | [(0.03)](/filings/0001193125-26-326295.md) | [0.00](/filings/0001193125-25-270039.md) | not reported | [(0.01)](/filings/0001193125-26-197777.md) | [(0.01)](/filings/0001193125-26-326295.md) |
| Free cash flow | $m | [3.3 d](/filings/0001193125-25-270039.md) | [4.0 d](/filings/0001193125-26-085678.md) | [(1.0)](/filings/0001193125-26-197777.md) | [(2.9) d](/filings/0001193125-26-326295.md) | [0.1 d](/filings/0001193125-25-270039.md) | [4.9 d](/filings/0001193125-26-085678.md) | [(3.3)](/filings/0001193125-26-197777.md) | [(3.5) d](/filings/0001193125-26-326295.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [160](/filings/0000950170-24-026195.md) | [188](/filings/0000950170-25-027906.md) | [187](/filings/0001193125-26-085678.md) | [201](/filings/0001193125-26-085678.md) | [234](/filings/0001193125-26-085678.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(30.7%)](/filings/0000950170-24-026195.md) | [(18.1%)](/filings/0000950170-25-027906.md) | [(16.1%)](/filings/0001193125-26-085678.md) | [(7.1%)](/filings/0001193125-26-085678.md) | [(3.7%)](/filings/0001193125-26-085678.md) |
| Net margin | % | [(34.1%)](/filings/0000950170-24-026195.md) | [(22.7%)](/filings/0000950170-25-027906.md) | [(20.1%)](/filings/0001193125-26-085678.md) | [(10.4%)](/filings/0001193125-26-085678.md) | [(6.7%)](/filings/0001193125-26-085678.md) |
| Diluted EPS | $ per share | [(0.32)](/filings/0000950170-24-026195.md) | [(0.24)](/filings/0000950170-25-027906.md) | [(0.21)](/filings/0001193125-26-085678.md) | [(0.11)](/filings/0001193125-26-085678.md) | [(0.08)](/filings/0001193125-26-085678.md) |
| Free cash flow | $m | [(34.8)](/filings/0000950170-24-026195.md) | [(27.6)](/filings/0000950170-25-027906.md) | [(47.8)](/filings/0001193125-26-085678.md) | [8.5](/filings/0001193125-26-085678.md) | [1.1](/filings/0001193125-26-085678.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cers/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $64.9m | 22,215,127 |  | Added +639,708 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $52.4m | 17,932,099 |  | Reduced −1,229,049 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $25.0m | 8,563,424 |  | Added +431,646 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $18.7m | 6,395,431 |  | Reduced −3,612,914 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $16.0m | 5,485,983 |  | Added +1,754,832 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $15.0m | 5,119,019 |  | Added +481,579 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $13.9m | 4,753,962 |  | Added +539,060 |
| [Senvest Management, LLC](/funds/1328785.md) | 2026-06-30 | $13.5m | 4,614,061 |  | Added +500,000 |
| [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $12.1m | 4,139,532 |  | Reduced −377,074 |
| [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $12.1m | 4,132,534 |  | Reduced −384,072 |

## Recent filings

[All 1,132 filings](/companies/cers/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 16:44 ET | [10-Q](/filings/0001193125-26-326295.md) | Quarterly report, period 2026-06-30 | 0001193125-26-326295 |
| 2026-07-30 | 16:03 ET | [8-K](/filings/0001193125-26-326093.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-326093 |
| 2026-07-10 | 16:35 ET | [8-K](/filings/0001020214-26-000015.md) | 5.02 Departure or appointment of officers or directors | 0001020214-26-000015 |
| 2026-06-08 | 16:20 ET | [8-K](/filings/0001193125-26-261794.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0001193125-26-261794 |
| 2026-06-03 | 16:17 ET | [8-K](/filings/0001193125-26-255488.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-255488 |
| 2026-04-30 | 17:05 ET | [10-Q](/filings/0001193125-26-197777.md) | Quarterly report, period 2026-03-31 | 0001193125-26-197777 |
| 2026-04-30 | 16:02 ET | [8-K](/filings/0001193125-26-197129.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197129 |
| 2026-04-22 | 12:00 ET | [DEF 14A](/filings/0001020214-26-000011.md) | Proxy statement, period 2026-04-22 | 0001020214-26-000011 |
| 2026-04-21 | 16:21 ET | [8-K](/filings/0001020214-26-000007.md) | 5.02 Departure or appointment of officers or directors | 0001020214-26-000007 |
| 2026-03-16 | 17:18 ET | [8-K](/filings/0001193125-26-108629.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-108629 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-085678.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/aab88bc2-5cb4-4d19-ae1a-ccad27fddbc1)

## About the filer

- CIK: 1020214
- Tickers: CERS
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.